CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

The Department of Health and Human Services plans to cancel contracts and pull funding for some vaccines being developed to ...

The controversial move affects development of vaccines against COVID-19, flu and H5N1, drawing criticism from public health ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to ...

So far, studies have shown that mRNA vaccines -- those made by Pfizer and Moderna -- maintain more than 90% efficacy six months after getting vaccinated. And scientists say it's likely much longer.

The U.S. Food and Drug Administration approved Pfizer and Moderna's updated COVID-19 vaccines amid a summer surge and ahead of an expected winter spike.